Lately, pharma companies have dominated the over-the-counter drug rankings, capturing the top 7 spots in the field and taking pure-play consumer companies down a notch. And according to Emma Walmsley, the CEO of GlaxoSmithKline and Novartis' consumer health JV, that should come as no surprise.
Batman and Superman can add another superhero to their ranks at publisher DC Comics, and that's Scott. The teenage protagonist and his trusty sidekick--Turbo the toy dog--feature in the company's latest graphic novel, which Novartis partnered to create for teens with tuberous sclerosis complex.
Hillary Clinton's plan to take away drugmakers' advertising tax deductions gets a resounding "no" from ad industry trade groups. While the ad executives aren't taking a stance on the rest of Clinton's drug-pricing plan, the advertising proposal gets a thumbs down.
Some industry-watchers foresee biosimilars gutting Humira sales not too far into the future, though maker AbbVie disagrees. If that scenario does play out, though? The Illinois pharma has room to pare down its marketing expenses, according to one analyst.
Last week, Apple stirred a long-simmering controversy into a raging debate: It unveiled ad blocking in its newest operating system. iPhone and iPad users of iOS 9 can now quickly and easily download blocking software to knock out ad units including display and banner ads, pop-up ads and autoplay videos.
While pharma critics often complain about too much TV advertising, a new study says it might be money well spent--for companies and their shareholders, at least.
Say cheese, bus shelter ad. Janssen's Prezcobix campaign advocates a new way for potential patients to talk to their doctors: Snap a picture and share it.
An old drug with a new trick? We'll see. After a long DTC hiatus, Bristol-Myers Squibb is taking a new tack with advertising its rheumatoid arthritis drug Orencia. The campaign for the decade-old drug emphasizes long-term relief and uses the new tagline, "See your RA in a different way."
DTC advertising drove a double-digit jump for Allergan's facial aesthetic business last quarter. And with generics now pouncing on blockbuster Namenda, the company is hoping it can repeat that ad-campaign success for its new Alzheimer's treatment.
There's been lots of hullaballoo surrounding Sanofi and MannKind's launch of inhaled insulin Afrezza, but for the arrival of the pair's first DTC campaign? Not so much.